Trial · NCT05355337
Registered outcomes45
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 45
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Adverse events | 9 weeks | Number and severity of adverse events |
| Secondary | Effect on task-based brain signal variability in the reward circuit | 9 weeks | BOLD-signaling during functional magnetic resonance imaging (fMRI) with Monetary Incentive Delay (MID)-task measuring Blood-Oxygen Level Dependent (BOLD) imaging pre/post treatment: Change in BOLD signals in nucleus accumbens from baseline to week 9 |
| Secondary | L-DOPA, blood: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of L-DOPA in blood sample from baseline to week 9 |
| Secondary | L-DOPA, CSF: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of L-DOPA in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | Homovanillic acid, blood: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of homovanillic acid in blood sample from baseline to week 9 |
| Secondary | Homovanillic acid, CSF: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of homovanillic acid in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | BH4, blood: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of tetrahydrobiopterin (BH4) in blood sample from baseline to week 9 |
| Secondary | BH4, CSF: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of tetrahydrobiopterin (BH4) in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | Tyrosine, blood: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of tyrosine in blood sample from baseline to week 9 |
| Secondary | Tyrosine, CSF: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of tyrosine in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | Phenylalanine, blood: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of phenylalanine in blood sample from baseline to week 9 |
| Secondary | Phenylalanine, CSF: biomarker of dopaminergic neurotransmission | 9 weeks | Change in levels of phenylalanine in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | IL-6, blood: biomarker of inflammation | 9 weeks | Change in levels of interleukin-6 (IL-6) in blood sample from baseline to week 9 |
| Secondary | IL-6, CSF: biomarker of inflammation | 9 weeks | Change in levels of interleukin-6 (IL-6) in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | IL-1b, blood: biomarker of inflammation | 9 weeks | Change in levels of interleukin-1b (IL-1b) in blood sample from baseline to week 9 |
| Secondary | IL-1b, CSF: biomarker of inflammation | 9 weeks | Change in levels of interleukin-1b (IL-1b) in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | IFN-y, blood: biomarker of inflammation | 9 weeks | Change in levels of interferon gamma (IFN-y) in blood sample from baseline to week 9 |
| Secondary | IFN-y, CSF: fluid biomarker of inflammation | 9 weeks | Change in levels of interferon gamma (IFN-y) in cerebrospinal fluid sample from baseline to week 9 |
| Secondary | hs-CRP, blood: biomarker of inflammation | 9 weeks | Change in levels of high-sensitivity C-reactive peptide (hs-CRP) in blood sample from baseline to week 9 |
| Secondary | hs-CRP, CSF: biomarker of inflammation | 9 weeks | Change in levels of high-sensitivity C-reactive peptide (hs-CRP) in cerebrospinal fluid from baseline to week 9 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05355337/registered?page=2